Erlotinib (Tarceva) in Routine Clinical Practice in Patients With Advanced Non Small Cell Lung Cancer (NSCLC) After Failure of at Least One Prior Chemotherapy Regimen With Focus on the Elderly Patient.

Trial Profile

Erlotinib (Tarceva) in Routine Clinical Practice in Patients With Advanced Non Small Cell Lung Cancer (NSCLC) After Failure of at Least One Prior Chemotherapy Regimen With Focus on the Elderly Patient.

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Nov 2015

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms ELDERTAC
  • Sponsors Roche
  • Most Recent Events

    • 14 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Sep 2013 Planned end date changed from 1 May 2015 to 1 Aug 2014 as reported by ClinicalTrials.gov.
    • 04 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top